Loading
companiesCompany
Shionogi
Shionogi is a long-established Osaka pharmaceutical company, best known for antibiotics and antivirals, that developed the platinum chemotherapy nedaplatin sold in Japan as Aqupla.
Also called: Shionogi & Co., Ltd.塩野義製薬TSE:4507
Overview
Shionogi, founded in Osaka in 1878, is a research-based pharmaceutical company with strengths in infectious disease, including the antiviral Xofluza and the antibiotic cefiderocol, and in pain and central nervous system medicines. In oncology it developed nedaplatin (254-S), a second-generation platinum agent with less kidney toxicity than cisplatin, approved in Japan in 1995 as Aqupla for head and neck, lung, oesophageal, bladder, cervical, ovarian and testicular cancers.
Headquarters
Osaka, JP
Scorecard
All companies#246of 1244 companies, score 21
- modalities +2
- registry trials +19
0 approved, 0 in phase 3, 0 earlier, 0 targets, 92 registry studies. Formula on the scorecards page.
Type
Large pharma · TSE:4507
Stage
Public
Website
Founded
1878
EstablishedSecond-generation platinum cytotoxic, intravenous
Nedaplatin · Aqupla
Nedaplatin is a Japanese platinum drug, approved there in 1995, used for head and neck, oesophageal, lung, cervical and other squamous cancers as a gentler alternative to cisplatin on the kidneys; it has never been approved in the West.
drugs
EstablishedSecond-generation platinum cytotoxic, intravenous
Nedaplatin · Aqupla